As of today (31st August 2020) more than 25,000,000 subjects have been recognized worldwide to be infected with SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2), with almost 900,000 deaths. Italy, Spain, and France in Europe have been the first affected countries, along with the United Kingdom and, outside Europe, United States of America as well as Brazil have the highest number of deaths as well as of infected subjects. 1 The impact of respiratory virus infections on morbidity and mortality in patients with cancer is widely recognized, with a risk of being hospitalized which is fourfold higher compared to age-matched subjects. 2 In this epidemiological scenario, older persons with cancer are at particularly high risk of adverse outcomes, 3,4 because of their actual risk of getting the disease, as well as for a higher likelihood of being denied proper and timely cancer treatment in order to protect them from COVID-19